The FDA approved the first blood test for Alzheimer's, developed by Fujirebio Diagnostics. This test measures the ratio of two proteins in the blood, correlating with amyloid plaques in the brain, a key indicator of the disease. Previously, detection relied on brain scans or spinal fluid analysis. The test aims to enable earlier diagnosis and treatment with recently approved drugs that slow disease progression, offering patients potentially more time with independence. The test is authorized for use in clinical settings alongside other clinical information for patients showing cognitive decline.

Prepared by Olivia Bennett and reviewed by editorial team.